Novel Rx
Robert B Chao, MD doctorRBC
4 years 11 months ago
Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20
Dr. John Cush RheumNow
4 years 11 months ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
Bella Mehta bella_mehta
4 years 11 months ago
How would you change csDMARDS and bDMARDS a few days before vaccination - if/when #COVID19 KILLED vaccine comes in (Assuming live vaccine would need strict medication management.) #ACR20 @RheumNow
David Liew drdavidliew
4 years 11 months ago
DVT/PE has been the sticking point for baricitinib in RA.
DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either.
Every drug has pros/cons; it's how we manage risk that counts...
#ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ
Richard Conway RichardPAConway
4 years 11 months ago
Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/LfjqZpnGCh
Abatacept in RA and ILD Patients: Dr Richard Conway
Dr. Richard Conway discusses abstract #0233 presented Friday at the 2020 ACR virtual annual meeting.
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list.
k dao KDAO2011
4 years 11 months ago
4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6,
cirrhosis NNH 1000
5.LoDoCo2: colchicine prevents MACE: NNT 36
6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ:
NNH 600
Peter Nash drpnash
4 years 11 months ago
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
American College of Rheumatology ACRheum
4 years 11 months ago
The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
ATS Clinical Problems Assembly ATSCPAssembly
4 years 11 months ago
Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/
Inadequate Response in Spondylitis: Dr. Olga Petryna
Dr. Petryna discusses two abstracts being presented at the ACR 2020 meeting: #0359 and #0371.
QD Clinic - Running out of Options
Difficult RA with Serious Infections and Limited options
Axial Involvement in Psoriatic Arthritis: Dr. Eric Ruderman Perspective
Dr. Eric Ruderman, Chicago, IL., provides his perspective on ACR 2020 coverage of axial involvement in Psoriatic Arthritis. During his remarks, he discusses ACR abstracts #0344, #1372, #2025 and #0505.
Poster Hall